Skip to content

Gender, Pain, and Placebo Analgesia

Effect of Participant Gender, Experimenter Gender, and Drug-Related Information on Placebo Analgesia

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00314392
Enrollment
74
Registered
2006-04-13
Start date
2006-09-30
Completion date
2007-12-31
Last updated
2008-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Experimental Pain

Keywords

Experimental pain, Placebo analgesia, Heart rate variability, Skin conductance

Brief summary

The response to standard pain stimuli in males and females is investigated, together with the effect of informing participants about the effect of a painkiller. Physiological response to pain is recorded.

Detailed description

The social context in which pain is reported has been found to modulate pain. Specifically, male participants reporting pain to female observers report significantly lower pain levels compared to male participants reporting to male observers. Female participants seem less affected by social context. This is a methodological problem in the study of pain and has consequences in the development of new drugs, and for pain research in general. The present study has two aims: To investigate whether social context affects also the placebo response to pain, i.e. the reduced pain often observed after administration of a an inert substance the participants believes to be a painkiller. It is hypothesized that placebo analgesia will be larger in males reporting pain to females. Secondly, heart rate variability and skin conductance, measures of parasympathetic and sympathetic activity, will be recorded, to investigate if social context affects not only pain report, but also pain response.

Interventions

BEHAVIORALInformation (behavior)

Sponsors

The Research Council of Norway
CollaboratorOTHER
University of Tromso
CollaboratorOTHER
University Hospital of North Norway
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* 18-40 years, healthy

Exclusion criteria

* pregnant, earlier serious disease or injury,

Design outcomes

Primary

MeasureTime frame
Pain report, heart rate variability, skin conductance

Secondary

MeasureTime frame
Subjective arousal

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026